Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: A case report

Thrombosis Journal

Volumn 14, Issue 1, 2016, Pages

  Shimizu, Kazuhiro ^a   Sasaki, Takeshi ^a   Tomaru, Takanobu ^a   Noike, Hirofumi ^a  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

Author keywords

Deep vein thrombosis; Edoxaban; Factor Xa inhibitor; Fondaparinux; Venous thromoboembolism

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; D DIMER; EDOXABAN; FONDAPARINUX; GLUCOSE; HEMOGLOBIN A1C; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BODY MASS; CASE REPORT; CELLULITIS; CLINICAL EXAMINATION; COMPRESSION STOCKING; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; ECHOCARDIOGRAPHY; ECHOGRAPHY; ELEVATED BLOOD PRESSURE; FEMORAL VEIN; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LABORATORY TEST; LEG PAIN; LEG SWELLING; LEG THROMBOSIS; MALE; MEDICAL HISTORY; MIDDLE AGED; PHYSICAL EXAMINATION; POPLITEAL VEIN; PULMONARY ARTERY; SKIN REDNESS; SOLEUS MUSCLE;

EID: 84979536631     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/s12959-016-0089-x     Document Type: Article

References (20)

1. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379:1835-46.
2. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010;8:2458-68.
3. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement: a randomised double-blind dose-response study. Thromb Haemost. 2010;104:642-9.
4. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-41.
5. Nakamura M, Miyata T, Ozeki Y, Takayama M, Komori K, Yamada N, et al. Current venous thromboembolism management and outcomes in Japan. Circ J. 2014;78:708-17.
6. Lozano F, Trujillo-Santos J, Barrón M, Gallego P, Babalis D, Santos M, et al. Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs. J Vasc Surg. 2014;59:1362-7.
7. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Subcutaneous fondaprinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349(18):1695-702.
8. Spyropoulos AC. Outpatient-based treatment protocols in the management of venous thromboembolic disease. Am J Manag Care. 2000;6(20 Suppl):1034-44.
9. Hokusai VTE Investigators, Büller HR, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-15.
10. Schulman S, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764-72.
11. Schulman S, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-52.
12. Grip LT, Ruff CT, Giugliano RP. New oral antithrombotic strategies: 2013 update on atrial fibrillation. Hot Topics Cardiol. 2013;8(31):7-19.
13. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250-5.
14. Zahir H, Matsushima N, Halim AB, He L, Zhang G, Lee F, et al. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. Thromb Haemost. 2012;108(1):166-75.
15. Laporte S, MIsmetti P, Decousus H, Uresandi F, Otero R, Lobo JL, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: Finding from the Registro Informatizado de la Enfermedad ThromboEmbolica venosa (RIETE) Registry. Circulation. 2008;117:1711-6.
16. Vítovec M, Golán L, Roztocil K, Linhart A. The development of persistent thrombotic masses in patients with deep venous thrombosis randomized to long-term anticoagulation treatment. Vasa. 2009;38:238-44.
17. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. J Thromb Haemost. 2003;89:409-19.
18. Morishima Y, Kamisato C, Honda Y. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats. Eur J Pharmacol. 2014;742:15-21.
19. Morishima Y, Honda Y, Kamisato C, Shibano T. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats. Thromb Res. 2013;132:234-9.
20. Swartz MN. Cellulitis. N Engl J Med. 2004;350:904-12.